Novartis announced plans to build a fourth US manufacturing facility for radioligand therapy (RLT) in Winter Park, Florida.[2][1] The plant will have an area of 35,000 square feet and will be operational by 2029.[2][1] It is part of a $23 billion investment in the US announced in April 2025.[2][4] The new facility will strengthen the specialized supply chain and manufacturing of RLT medicines for patients in the Southeastern US.[2][5] RLT is a precision cancer treatment that combines a tumor-targeting molecule with a radioisotope, delivering radiation directly to the tumor while minimizing damage to healthy tissue.[2][5] Each dose of RLT is prepared individually and its administration is time sensitive, so proximity to treatment centers is key.[2][5] Novartis maintains a dose delivery rate above 99% on the scheduled day.[2][5] The company is also expanding existing plants in Indiana and New Jersey and plans a fifth in the US.[4][5]